Stifel Financial Corp Grows Position in Sanofi SA (NYSE:SNY)

Share on StockTwits

Stifel Financial Corp raised its position in Sanofi SA (NYSE:SNY) by 2.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 211,659 shares of the company’s stock after purchasing an additional 4,804 shares during the quarter. Stifel Financial Corp’s holdings in Sanofi were worth $9,819,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in SNY. Flagship Harbor Advisors LLC raised its holdings in shares of Sanofi by 30.2% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 1,380 shares of the company’s stock worth $59,000 after purchasing an additional 320 shares during the period. AE Wealth Management LLC raised its holdings in shares of Sanofi by 26.9% in the 2nd quarter. AE Wealth Management LLC now owns 6,057 shares of the company’s stock worth $262,000 after purchasing an additional 1,284 shares during the period. Commerzbank Aktiengesellschaft FI raised its holdings in shares of Sanofi by 13.4% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 30,620 shares of the company’s stock worth $1,325,000 after purchasing an additional 3,609 shares during the period. Logan Capital Management Inc. raised its holdings in shares of Sanofi by 11.5% in the 2nd quarter. Logan Capital Management Inc. now owns 29,452 shares of the company’s stock worth $1,274,000 after purchasing an additional 3,047 shares during the period. Finally, Greenleaf Trust raised its holdings in shares of Sanofi by 16.6% in the 2nd quarter. Greenleaf Trust now owns 16,542 shares of the company’s stock worth $716,000 after purchasing an additional 2,358 shares during the period. Institutional investors own 7.04% of the company’s stock.

In other news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total value of $48,611,959.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.00% of the stock is currently owned by company insiders.

SNY stock opened at $45.82 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi SA has a 1 year low of $40.00 and a 1 year high of $47.47. The firm has a market cap of $116.89 billion, a P/E ratio of 14.64, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. The stock has a 50-day simple moving average of $46.10 and a 200-day simple moving average of $43.85.

Sanofi (NYSE:SNY) last posted its earnings results on Thursday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.11. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The business had revenue of $10.56 billion during the quarter, compared to analyst estimates of $10.62 billion. On average, equities research analysts predict that Sanofi SA will post 3.1 EPS for the current year.

A number of research firms have recently issued reports on SNY. Sanford C. Bernstein began coverage on Sanofi in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $52.00 target price for the company. Guggenheim upgraded Sanofi from a “neutral” rating to a “buy” rating in a research note on Monday, September 23rd. UBS Group upgraded Sanofi from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 14th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Thursday, August 29th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, August 29th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Sanofi has a consensus rating of “Buy” and an average price target of $50.33.

Sanofi Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: What are the advantages of the Stochastic Momentum Index?

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.